 REDWOOD CITY, Calif., March 15, 2022 GLOBE NEWSWIRE -- Biomea Fusion, Inc. Nasdaq: BMEA, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it is scheduled to participate in a fireside chat at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2022 at 7:00am Pacific Time. Thomas Butler, Biomeas CEO and Chairman of the Board, will participate in the fireside chat. 